A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

The device helps identify NSCLC subjects who are likely to benefit from Daiichi Sankyo and AstraZeneca’s Datroway’s treatment ...

High-level results from the DESTINY-Breast09 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), in ...

DATROWAY ® (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative ...

In the Phase III DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) and Perjeta (pertuzumab) significantly improved ...

In 2019, the FDA approved Enhertu (fam-trastuzumab-deruxtecan-nxki) to treat adults with certain types of HER2-positive breast cancer. In 2022, the FDA expanded the use of Enhertu to treat ...

Below is a timeline of the actions the Trump administration or Congressional Republicans have taken that impact housing since President Trump took office on Jan. 20, 2025, along with additional ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has today (9 April 2025) approved trastuzumab deruxtecan (Enhertu) to treat people with solid tumours that have mutations in human ...

Civic action – whether through protest, prayer vigils or community organizing – is not just symbolic. It is a powerful mechanism for social transformation and legal accountability. Framing the return ...